Policy by press release

Oncorena's first patient treated with ONC175 (orellanine) in clinical phase I/II trial in patients with metastatic renal cancer and dialysis at Karolinska University Hospital in Stockholm, Sweden

Retrieved on: 
Monday, September 4, 2023

LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.

Key Points: 
  • LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.
  • The first treatment was conducted on August 8 without any complication at the Center for Clinical Cancer studies at Karolinska University Hospital, Stockholm, Sweden.
  • "I am happy to announce first patient, first treatment in our clinical phase I/II trial, Oncorella-1, with ONC175 (orellanine).
  • The clinical study, Oncorella-1, is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital, Stockholm, Sweden.

Oncorena's first patient treated with ONC175 (orellanine) in clinical phase I/II trial in patients with metastatic renal cancer and dialysis at Karolinska University Hospital in Stockholm, Sweden

Retrieved on: 
Monday, September 4, 2023

LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.

Key Points: 
  • LUND, Sweden, Sept. 4, 2023 /PRNewswire/ -- Oncorena announces first patient treated in the Phase I/II trial of the first-in-class compound, ONC175 (orellanine), in patients with metastatic renal cancer and dialysis.
  • The first treatment was conducted on August 8 without any complication at the Center for Clinical Cancer studies at Karolinska University Hospital, Stockholm, Sweden.
  • "I am happy to announce first patient, first treatment in our clinical phase I/II trial, Oncorella-1, with ONC175 (orellanine).
  • The clinical study, Oncorella-1, is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital, Stockholm, Sweden.

Buenaventura Announces Submission of Updated Uchucchacua Mine Plan

Retrieved on: 
Tuesday, August 29, 2023

This submission therefore completes the required process for the resumption of activities of the Uchucchacua mine, starting on September 1, 2023.

Key Points: 
  • This submission therefore completes the required process for the resumption of activities of the Uchucchacua mine, starting on September 1, 2023.
  • Buenaventura will initiate relevant maintenance work and expects the processing plant commissioning to begin on September 1, ensuring processing plant operational readiness to receive ore from Uchucchacua and Yumpag.
  • The resumption of activities at the Uchucchacua processing plant also enables Buenaventura to perform metallurgical tests of up to 124,600 tons of ore from the Yumpag project’s pilot stope.
  • Buenaventura currently operates several mines in Peru (Orcopampa*, Uchucchacua*, Julcani*, Tambomayo*, La Zanja*, El Brocal and Coimolache).

Appia Receives Positive Assays Results - Announces Plans to Proceed with the Acquisition of Ionic Clay Project, Brazil

Retrieved on: 
Tuesday, May 30, 2023

269 Samples Show Positive Correlation to Vendor's Results

Key Points: 
  • Early indications are that the mineralogy is primarily bastnaestite and monazite with clays that are preferentially enriched in the valuable magnetic rare earth elements.
  • Historic work by the Vendors indicates that the magnetic REEs represent +/- 25% of the total REEs found within the project area.
  • The Cachoeirinha Project (PCH Project) is located within the Tocantins Structural Province in the Brasília Fold Belt, more specifically, the Arenópolis Magmatic Arc.
  • The positive results of the recent geochemical exploration work carried out to date indicates the potential for REEs and Niobium within lateritic ionic adsorption clays.

Appia Completes Onsite Due Diligence on Rare Earths Ionic Clay Project, State of Goias, Brazil

Retrieved on: 
Wednesday, April 26, 2023

269 Samples Now Pending Assaying at SGS Labs in Brazil

Key Points: 
  • "In addition, there were two diamond drill holes originally completed by the Vendor's team but not previously assayed.
  • The entire lengths of the two diamond drill holes were sampled and included as part of the total sample package delivered for assaying."
  • A total of 269 samples were taken, and are now being processed at the SGS labs near Belo Horizonte, Brazil.
  • The positive results of the recent geochemical exploration work carried out to date indicates the potential for REEs and Niobium within lateritic ionic adsorption clays.

Appia Begins Due Diligence on Rare Earths Ionic Clay Project, State of Goiás, Brazil

Retrieved on: 
Wednesday, April 19, 2023

Identifies Strong Similarities to the Serra Verde Ionic Clay Project

Key Points: 
  • "The PCH project has significant potential for high levels of REEs in the upper layers of the clay structure.
  • The mineralization is in a Carbonatite complex, and the surrounding granites have weathered to develop ionic clay characteristics in the upper levels," stated Mr. Don Hains, Consulting Geologist and Senior Advisor to Appia.
  • "The regional mineralogy has very similar lithologies to Serra Verde ( See link to website here ) demonstrating the classic model of ionic clay structures.
  • Ionic clays can be mined with low-cost open pit mining techniques and processed using simple technologies," stated Stephen Burega, President.

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials

Retrieved on: 
Thursday, February 23, 2023

"We are pleased to have The Lind Partners as an investor," said Howard Doong, CEO of ABVC BioPharma.

Key Points: 
  • "We are pleased to have The Lind Partners as an investor," said Howard Doong, CEO of ABVC BioPharma.
  • "We are pleased to invest in ABVC to support their vision and growth initiatives," said Phillip Valliere, Managing Director at The Lind Partners.
  • "We believe 2023 will be an exciting year for ABVC as their drug pipeline meets expected key milestones."
  • If the Company makes a Monthly Payment in cash, the Company must also pay Lind a cash premium of 5% of such Monthly Payment.

Pear Therapeutics and BrightView Health Expand Pilot Program to Provide Prescription Digital Therapeutics for the Treatment of Substance Use Disorders

Retrieved on: 
Thursday, January 26, 2023

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health , an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with BrightView Health , an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs.
  • This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®.
  • “We believe reSET and reSET-O are beneficial to our patients, the community, and our health system.
  • Increase abstinence from a patient’s substances of abuse during treatment, and
    Increase retention in the outpatient treatment program.

Correction - Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Retrieved on: 
Wednesday, January 25, 2023

NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.

Key Points: 
  • NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.
  • NuraLogix technology, service and products are not a substitute for the clinical judgment of a health care professional.
  • ST. GEORGE, Utah, Jan. 25, 2023 /PRNewswire/ - Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.
  • CDL Health Scanner not only alerts drivers of potentially serious health concerns, but it also provides health education focused on the driver and guides them toward resources that can assist with lifestyle changes.

Correction - Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers

Retrieved on: 
Wednesday, January 25, 2023

ST. GEORGE, Utah, Jan. 25, 2023 /PRNewswire/ -- Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.

Key Points: 
  • NuraLogix technology, service and products are intended to improve your awareness of general wellness and health.
  • NuraLogix technology, service and products are not a substitute for the clinical judgment of a health care professional.
  • ST. GEORGE, Utah, Jan. 25, 2023 /PRNewswire/ -- Health in Transportation, a health and wellness solution provider for the transportation industry, released a revolutionary preventative health tool for drivers called CDL Health Scanner.
  • CDL Health Scanner not only alerts drivers of potentially serious health concerns, but it also provides health education focused on the driver and guides them toward resources that can assist with lifestyle changes.